Join
Live feed
·
PRReleasevia Quantisnow
Curis Inc. logo

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

ByQuantisnow·Wall Street's wire, on your screen.
CRIS· Curis Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRIS (Curis Inc.) and more on Quantisnow.